AVAPRO versus amlodipine
AVAPRO: Powerful systolic and diastolic blood pressure (SBP and DBP) reductions comparable to one of the most widely prescribed antihypertensive agents, amlodipine, at starting doses.
15
Primary end point: mean DBP change from baseline to Week 4.
Mean age, 51 years; 63% male; 87% Caucasian.
Dizziness was the most commonly reported adverse event.
Download additional study information following the full Prescribing Information.
AVAPRO versus losartan
AVAPRO: once-daily superior DBP-reducing power vs losartan at maximum once-daily doses.*
17,18
Kassler-Taub et al
17:
8-week, multicenter, randomized, double-blind, placebo-controlled comparative study.
Primary end point: mean DBP change from baseline to Week 8.
The most common adverse events were headache, musculoskeletal pain, dizziness, upper respiratory infection, and fatigue.
Download additional study information following the full Prescribing Information.
Superiority demonstrated in another well-controlled DBP reduction trial*
18
Oparil et al
18:
12-week, multicenter, randomized, double-blind, elective-titration, comparative study.
Primary end point: DBP change from baseline to Week 8.
The most common adverse events were dizziness and headache.
*These studies were conducted on hypertensive patients only and were designed to demonstrate significant DBP lowering between 2 ARBs. A comparison between once-daily AVAPRO and twice-daily losartan was not conducted in these studies.
